Literature DB >> 28077691

Establishment and baseline characteristics of a nationwide Danish cohort of patients with Ehlers-Danlos syndrome.

Marie-Louise Kulas Søborg1, Julie Leganger1, Laura Quitzau Mortensen1, Jacob Rosenberg1, Jakob Burcharth2.   

Abstract

Objectives: The aim of this study was to investigate national prevalence, general demographic characteristics and survival of Danish patients with Ehlers-Danlos syndrome (EDS). Method: A population-based cohort study was conducted using a database consisting of the entire Danish population alive at any given time between 1 January 2000 and 31 December 2012, based upon longitudinal Danish national registers. All patients with EDS were identified, and the cohort was described by disease prevalence, basic demographic characteristics, mean age at death and mortality for the observational period of 13 years.
Results: The cohort held 1427 unique persons with EDS, giving a national prevalence of 0.02%. The EDS population had a mean ( s . d .) age of 34.9 (18.6) years and comprised 73.9% females and 26.1% males. Of the cohort, 95.9% originated from Denmark and 57% were unmarried. We found that 31.6% of the cohort received state-granted subsidies, of which 77% were in the form of early retirement pension. Regarding educational status, 28.1% of the EDS cohort had completed primary education (⩽10th grade) as their highest educational level, while 71.9% had completed a higher level. During the observation period, 42 patients died, with a mean ( s . d .) age at death of 53.6 (21.7) years.
Conclusion: This study confirmed a small national prevalence of patients diagnosed with EDS and showed that the majority of patients diagnosed are female. The EDS cohort had a lower educational level, mean age and life expectancy compared with the background population and showed a predisposition for receiving state-granted subsidies.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  Denmark; Ehlers–Danlos syndrome; cohort; demography; epidemiology; register

Mesh:

Year:  2017        PMID: 28077691     DOI: 10.1093/rheumatology/kew478

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Prevalence of Obstructive Sleep Apnea in Joint Hypermobility Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Karim Sedky; Thomas Gaisl; David S Bennett
Journal:  J Clin Sleep Med       Date:  2019-02-15       Impact factor: 4.062

2.  Next-generation sequencing and analysis of consecutive patients referred for connective tissue disorders.

Authors:  Jacob Steinle; Waheeda A Hossain; Olivia J Veatch; Samuel P Strom; Merlin G Butler
Journal:  Am J Med Genet A       Date:  2022-07-29       Impact factor: 2.578

3.  Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison.

Authors:  Joanne C Demmler; Mark D Atkinson; Emma J Reinhold; Ernest Choy; Ronan A Lyons; Sinead T Brophy
Journal:  BMJ Open       Date:  2019-11-04       Impact factor: 2.692

4.  Craniofacial Morphology and Upper Airway Dimensions in Patients with Hypermobile Ehlers-Danlos Syndrome Compared to Healthy Controls.

Authors:  Liselotte Sonnesen; Tessie Pawlik; Eva Fejerskov Lauridsen
Journal:  J Oral Maxillofac Res       Date:  2021-06-30

5.  The Internet Knows More Than My Physician: Qualitative Interview Study of People With Rare Diseases and How They Use Online Support Groups.

Authors:  Sadaf Ashtari; Adam Daniel Taylor
Journal:  J Med Internet Res       Date:  2022-08-25       Impact factor: 7.076

6.  Temporomandibular disorders, bite force and osseous changes of the temporomandibular joints in patients with hypermobile Ehlers-Danlos syndrome compared to a healthy control group.

Authors:  Karen Bech; Frederikke Maria Fogh; Eva Fejerskov Lauridsen; Liselotte Sonnesen
Journal:  J Oral Rehabil       Date:  2022-06-30       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.